Abstract
Fecal microbiota transplant is a promising therapy for ulcerative colitis. Parameters maximizing effectiveness and tolerability are not yet clear, and it is not known how import the transmission of donor microbes to patients is. Here (clinicaltrails.gov: NCT03006809) we have tested the effects of antibiotic pretreatment and compared two modes of maintenance dose delivery, capsules versus enema, in a randomized, pilot, open-label, 2×2 factorial design with 22 patients analyzed with mild to moderate UC. Clinically, the treatment was well-tolerated with favorable safety profile. Of patients who received antibiotic pretreatment, 6 of 11 experienced remission after six weeks of treatment, versus 2 of 11 non-pretreated patients (odds ratio: 1.69, 95% confidence interval: -0.25 to 3.62). No significant differences were found between maintenance dosing via capsules versus enema. In exploratory analyses, microbiome turnover at both the species and strain levels was extensive and significantly more pronounced in the pretreated patients. Associations were also revealed between taxonomic turnover and changes in the composition of primary and secondary bile acids. Together these findings suggest that antibiotic pretreatment contributes to microbiome engraftment and possibly clinical effectiveness, and validate longitudinal strain tracking as a powerful way to monitor the dynamics and impact of microbiota transfer.
Competing Interest Statement
- YMP is an employee of Symbiome, Inc. - ZK is an employee/shareholder at Finch Therapeutics - SVL is co-founder and shareholder of Siolta Therapeutics, Inc. and serves as both a consultant and a member of its Board of Directors. - KSP is on the scientific advisory board of Phylagen. - NE has received research support from Finch Therapeutics and Assembly Biosciences, and has been a consultant for Federation Bio and Ferring Pharmaceuticals. - All other authors declare no competing interests
Clinical Trial
NCT03006809 (ClinicalTrials.gov)
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03006809
Funding Statement
- BJS and BZ are supported by funding from the National Institutes of Health grant number 5T32DK007007. - KSP and BJS were supported by funding from National Science Foundation grant number 1563159, Chan Zuckerberg Biohub, and Gladstone Institutes. - NE, MZ and YMP were supported by funding from the Kenneth Rainin Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent for voluntary participation in this institutional review board-approved protocol (UCSF IRB study number: 16-20066). FMT was approved for use for this indication under FDA Investigational New Drug application (IND 16467). This study was registered at Clinicaltrials.gov (NCT03006809).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The title has been amended to avoid potential over-interpretation of a trend towards higher remission in antibiotic pre-treated individuals. We have expanded discussion of study limitations to include: (1) the lack of a no-treatment control group, (2) imbalances between male and female subject assignment across donors, and (3) the exclusive use of stool samples and no measurements of the mucosa-adherent microbiota. We have added an analysis to the Supplementary Materials considering the possibility of microbiome profiles clustering by patient sex. The introduction and discussion now reference tools like SourceTracker that have been used in past studies to detect transmission of microbiota between environments. We now include results in the Supplementary Materials from a survey of donor and patient strain coexistence at follow-up.
Data Availability
Amplicon sequences from the 16S rRNA gene and metagenomic sequences with human reads removed were uploaded to the SRA under BioProject PRJNA737472 and will be released upon publication. All code and metadata needed to reproduce our results are available at doi:10.5281/zenodo.5851803.
https://github.com/bsmith89/ucfmt2
